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A B S T R A C T
Purpose: Impact of adverse effects of antiepileptic medications (AEDs) such as cognitive side effects
(CSEs) on quality of life can be signiﬁcant. Here we provide an extended follow-up to our earlier study to
investigate the predictors of cognitive side effects (CSEs) and relative frequency of CSEs among all
commonly used AEDs.
Methods: In this retrospective study, medical records of 2860 adult outpatients with epilepsy seen at our
center over a 12-year period who had taken one or more AEDs were examined.
Results: Of 2860 patients, 15% had intolerable CSEs attributed to at least one AED. On multiple logistic
regression analysis, independent predictors of intolerable CSEs were lack of intellectual disability and
polytherapy. In polytherapy, we found that intolerable CSEs were most commonly seen with topiramate
(22.8% of 281 patients), signiﬁcantly more than with almost all other AEDs. This was true in
monotherapy as well, with signiﬁcantly more intolerable CSEs occurring with topiramate (18.5% of 54
patients) than with gabapentin, carbamazepine, lamotrigine, and levetiracetam. AEDs with consistently
low rates of ICSEs included gabapentin, pregabalin, lamotrigine, levetiracetam and carbamazepine.
Conclusion: These data can help facilitate selection of AEDs.
 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.
Contents lists available at ScienceDirect
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Antiepileptic medications (AEDs) remain the mainstay of
treatment in epilepsy. Currently, over 20 FDA-approved AEDs
are available for use in management of patients with epilepsy.
Adverse effects resulting from AEDs are common. The impact of
adverse effects on the overall health, as assessed with quality of life
(QOL) scales, is signiﬁcant, with adverse medication effects having
the strongest correlation with health-related QOL in one study [1].
Among a number of potential adverse effects that can result from
the use of AEDs, subjective cognitive side effects (CSEs) may
necessitate either discontinuation or dose reduction if symptoms
are felt to be intolerable.* Corresponding author at: Columbia Comprehensive Epilepsy Center, The
Neurological Institute, 710 West 168th Street, Box 210, New York, NY 10032,
USA. Tel.: +1 212 305 1742; fax: +1 212 305 1450.
E-mail address: hc323@columbia.edu (H. Choi).
http://dx.doi.org/10.1016/j.seizure.2015.03.013
1059-1311/ 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.In a previous study by our group [2], we examined the
prevalence of CSEs among commonly used AEDs and the potential
predictors of CSEs among 1694 adult epilepsy patients followed at
a single tertiary care center between 2000 and 2005. Since our
previous paper, several new AEDs have been approved by the FDA.
The newly approved AEDs include lacosamide, pregabalin,
ruﬁnamide, vigabatrin and clobazam (although the latter two
were included in the prior study via importation from other
countries). Also, some medications have become much more
popular, such as levetiracetam [3]. Although some studies indicate
that the risk of CSEs of the newly approved AEDs may be favorable
[4,5], few data exist on comparison of CSEs of these new AEDs
against all available AEDs.
We herein report an extended follow-up of our prior study,
adding 1166 patients and 3 new AEDs with follow-up data up to
year 2012 (7 years later than the prior study). We examined the
relative frequency of CSEs attributed to speciﬁc AEDs, including the
5 recently approved AEDs. We also investigated the non-AED
predictors of CSEs. With longer follow-up, more patients, and
inclusion of 5 new AEDs, this study provides a more comprehensive
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subjective CSEs.
2. Materials and methods
Methodology was similar to that of our prior publication [2]. We
reviewed the medical charts of 2860 adult (at least 16 years of age
at ﬁrst visit) outpatients seen by their treating epilepsy attending
at the Columbia Comprehensive Epilepsy Center between January
1, 2000 and November 19, 2012 and with outcome available for at
least one AED trial. During the 12-year study period, of the 2860
patients, 2192 patients were started on one or more AEDs at our
center. AEDs started for the ﬁrst time at our center were classiﬁed
as ‘‘newly started’’ AEDs (carbamazepine [CBZ], clobazam [CLB],
felbamate [FBM], gabapentin [GBP], lacosamide [LCM], levetir-
acetam [LEV], lamotrigine [LTG], oxcarbazepine [OXC], Phenobar-
bital [PB], phenytoin [PHT], pregabalin [PGB], primidone [PRM],
ruﬁnamide [RFM], tiagabine [TGB], topiramate [TPM], vigabatrin
[VGB], valproic acid [VPA], or zonisamide [ZNS]).
Documentation of CSEs that developed during the use of any
AED was obtained by review of all available notes in the medical
chart, including review of a symptom checklist completed at each
visit, telephone notes, and physician notes. Attribution of
subjective CSEs to a particular AED was made based on physician
notes. Cognitive side effects were categorized as one of the
following: (1) language problems such as aphasia, anomia/word-
ﬁnding difﬁculty, (2) memory difﬁculty, or (3) psychomotor/
cognitive slowing, confusion/disorientation or encephalopathy.
‘‘Intolerable’’ CSEs (ICSEs) were deﬁned as CSEs attributed to an
AED resulting in dose reduction or discontinuation of that AED. In
the situation of multiple concomitant AEDs, CSE attribution to an
AED was made only if the medical chart speciﬁed an AED.
Data abstraction based on review of medical records included
patient characteristics including medical and psychiatric history,
concomitant medications and dosages, laboratory test results, side
effects, and efﬁcacy measures. Data were entered into an electronic
database by trained research assistants. As there was one person
entering data per patient medical record, no inter-rater reliability
was evaluated. However, on a regular basis, the physician
investigator performed random review of data entered by all
research assistants. Additionally, automatic error reports were
generated, for example, highlighting inconsistencies between
syndrome and seizure type. Other possible errors were detected,
such as ﬂags for ‘‘outlier’’ doses and serum levels that fell more
than 2 SD from the mean. These were then manually checked for
accuracy.
2.1. Predictor analysis
To investigate potential non-AED predictors of ICSEs, we
examined 77 variables (Supplementary Table 1), which included
various demographics, medical and psychiatric history, and
epilepsy-related variables. To evaluate the possible predictors of
ICSEs, we ﬁrst performed univariate analysis using a simple logistic
regression model to predict the occurrence of ICSEs. All variables
found to be associated with ICSE in the univairate model with an
a  0.1 level were then ﬁt in the multiple logistic regression
analysis using ‘‘enter’’ selection method (with an a  0.05). The
multiple logistic regression analysis, allowed us to test for
associations between each variable controlling for other variables
in the model and to investigate the extent to which these variables
explained the observed between-patient variation in ICSE.
Signiﬁcance for multiple logistic regression analysis was set at
p < 0.003 (based on Bonferroni correction of p = 0.05/17). The
denominator of 17 represents the number of signiﬁcant variables
that were included in the ﬁnal multiple logistic regression analysis.2.2. Drug comparison
We investigated the frequency of ICSEs attributed to a newly
started AED. We compared the rates of AED-related ICSEs among
(a) 1871 patients with AEDs newly started as part of polytherapy,
and (b) 1243 patients who were started for the ﬁrst time on speciﬁc
AEDs as monotherapy (may or may not be drug naı¨ve at the time of
initiation of these AEDs) at our center.
For comparison of rates of ICSEs between AEDs, we performed a
series of pairwise x2. The rate of ICSEs from one AED was compared
with that of another AED in a two-by-two comparison. When
x2analyses included expected values <5, we used Fisher’s exact
test. In consideration of multiple pairwise comparisons occurring
for each AED, we chose a = 0.005 and interpreted the results in
terms of consistent patterns seen in the relative rates of intolerable
CSEs attributed to the AEDs to avoid Type I error.
We also examined whether the occurrence of ICSEs was related
to differences in AED dose load (i.e., dosage). First, AED load was
calculated for each individual patient by dividing the AED dose at
the time of ICSE by the deﬁned daily dose (DDD) of that particular
AED [6]. The DDD is the maintenance dose of an AED used for its
main indication in adults considered by the World Health
Organization (WHO) [7]. The DDD values are listed in Supplemen-
tary Table 8. As an example, the AED load for a patient on 400 mg of
medication X at the time of ICSE would be calculated as 400 mg
divided by the DDD of medication X. If the DDD was 200 mg, the
AED load would equal 2. Then, for each AED, we compared the
mean AED load of patients with ICSE with that of patients without
ICSE for that particular AED, using one-way analysis of variance
(ANOVA).
All analyses were conducted with IBM SPSS Statistics V19
(Chicago, IL).
3. Results
Brieﬂy, the demographics and characteristics of the 2860
patients (Table 1) included a mean age of 40.6 years. The majority
of patients (71%) had focal epilepsy. Patients tried an average of 3.5
distinct drug combinations and stayed on an AED for a median
duration of 40 months.
Of the entire cohort (n = 2860), 428 (15.0%) patients had
intolerable CSEs (ICSEs) attributed to at least one AED. Among 1871
patients who were newly started on an AED in polytherapy, 210
patients (11.2%) had ICSEs. Among the 1243 patients who were
newly started on an AED in monotherapy, 94 patients (7.6%) had
ICSEs. The number of patients who tried each AED, frequency of
AED use by epilepsy type, and mean maximum dose for each AED
(Table 1) were indicative of the practice pattern at this single site
on a group level.
3.1. Predictors of ICSEs
In the univariate analysis comparing the occurrence of ICSE and
each independent variable individually, we found signiﬁcant
associations between ICSE and 17 variables (as listed in Table 2).
A multiple logistic regression model was then ﬁt to determine
independent non-AED predictors of ICSEs, including all factors that
were found to be associated with the outcome with p < 0.1 in
univariate analysis. To address the issue of multiple comparisons,
we set the p value for signiﬁcance in multivariate analysis at
p < 0.003 (based on Bonferroni correction), with the p value for
‘‘trend’’ as 0.003 < p < 0.05 [8]. Intellectual disability (OR = 0.42,
p = 0.001), and use of AED in polytherapy (OR = 3.41, p < 0.001)
were found to be signiﬁcantly associated with ICSEs (with
intellectual disability being ‘‘protective’’), controlling for the other
factors in the model (Table 2). All of the variables signiﬁcant in
Table 1
Patient demographics (n = 2860).
AEDc n % Male Mean age (years) Epilepsy typea (%) Mean
weight (kgs)
Mean maximum
dose (mg/day)b
Median duration
(months) (max)
Focal 18 Gen. Sx. Gen. Unclear Focal & 18GEN
CBZ 834 48.7 40.8 80.0 10.0 4.4 5.2 0.5 75.8 1051  524 22 (344)
CLB 302 54.0 44.6 90.0 2.3 6.0 1.0 0.7 76.0 23  17 29 (158)
FBM 118 35.0 41.0 60.7 22.2 12.0 1.7 3.4 71.6 2947  1147 24 (128)
GBP 498 46.0 46.2 84.3 6.5 3.7 4.9 0.6 73.5 2131  1684 13 (159)
LCM 142 46.5 42.8 88.7 2.8 5.0 2.8 0.7 74.9 349  185 7 (206)
LEV 1286 47.2 42.3 72.3 18.1 4.4 4.0 1.2 75.2 2200  1443 18 (206)
LTG 1772 44.8 41.8 72.4 17.5 3.3 5.7 1.1 73.8 524  313 34 (206)
OXC 379 50.1 41.6 88.3 3.7 2.7 4.3 1.1 75.4 1483  769 8 (142)
PB 171 41.5 42.2 71.0 17.8 5.9 4.1 1.2 75.0 128  93 14 (486)
PGB 322 42.9 46.4 87.0 1.9 6.6 2.8 1.6 73.3 384  246 15 (148)
PHT 650 54.1 44.4 75.5 13.5 3.0 6.7 1.3 75.7 383  158 12 (449)
PRM 66 54.5 45.4 66.7 18.2 10.6 4.5 0.0 74.6 631  353 29 (285)
RFM 92 39.1 41.1 32.6 26.1 38.0 0.0 3.3 71.4 2289  1094 10.5 (56)
TGB 43 37.2 41.2 83.7 2.3 4.7 4.7 4.7 74.9 16  37 6 (75)
TPM 456 35.1 38.9 67.0 18.5 8.4 4.6 1.5 75.8 280  246 13 (152)
VGB 62 56.5 42.4 79.0 1.6 19.4 0.0 0.0 73.4 3153  966 27.5 (268)
VPA 621 51.0 38.7 43.4 42.1 8.5 4.6 1.5 75.6 1562  885 22 (292)
ZNS 505 36.8 38.5 66.6 21.6 7.0 3.0 1.8 74.2 360  198 10 (123)
Cohort 2860 45.8 40.6 71.1 18.5 3.4 6.0 1.0 74.9 40 (486)
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; CLB: clobazam; FBM: felbamate; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine;
OXC: oxcarbazepine; PB: phenobarbital; PGB: pregabalin; PHT: phenytoin; PRM: primidone; RFM: ruﬁnamide; TGB: tiagabine; TPM: topiramate; VGB: vigabatrin; VPA:
valproate; ZNS: zonisamide.
a Epilepsy type: 18 Gen.: primary generalized epilepsy; Sx. Gen.: symptomatic generalized epilepsy.
b Mean  SD.
c Only AEDs taken in 20 or more patients are shown.
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Table 2. Nagelkerke R2 on the model level was 0.07, indicating that
the model accounts for only 7% of the variability in the dependent
variable.
3.2. Comparison of ICSE rates for speciﬁc AEDs
We compared the relative rates of ICSEs associated with each
when AEDs were newly started as part of polytherapy (Supple-
mentary Table 2 and Supplementary Figure 1), and relative rates of
ICSEs when AEDs were newly started in monotherapy (Supple-
mentary Table 3 and Supplementary Figure 2). We repeated the
analysis, examining the rate among those without intellectual
disability (Supplementary Table 4).Table 2
Non-AED predictorsa of AED ICSEs in patients with Epilepsy (n = 2860).
Attribute N Univariate
odds ratio
Univariate
p-value
Female gender 1548 1.34 0.006 
Intellectual disability 214 0.62 0.04 
Status epilepticus 191 1.38 0.095 
Seizure clusters 276 1.49 0.013 
Diabetes 95 1.62 0.058 
Migraine 315 1.40 0.029 
CNS infection 131 1.63 0.024 
Dementia 41 2.08 0.04 
Family history: seizures 53 0.22 0.034 
Prior neurosurgery 186 1.64 0.007 
Complex partial 1431 1.43 0.001 
Absence 293 1.33 0.071 
Drop astatic 29 2.99 0.005 
Lobe: frontal 275 1.35 0.07 
Lobe: Parietal 87 1.59 0.081 
Polytherapy during follow-up 2124 1.48 <0.001 
a Predictors tested: 77 variables including sex, age, weight, seizure type, epilepsy synd
with p < 0.1 in univariate analysis are shown here. Only variables with p < 0.003 in m
(0.003 < p < 0.05).3.2.1. Relative rates of ICSEs from newly started AEDs in polytherapy
When examining the rate of ICSEs associated with newly
started AEDs (when AEDs were part of polytherapy), the highest
rate of ICSEs occurred with TPM (22.8%) (Table 3). When TPM was
compared against other AEDs in head-to-head comparison
(Supplementary Table 2), the rate of CSEs intolerability from
TPM was signiﬁcantly higher (p  0.001) than all AEDs except PB,
PRM, and TGB. Among the newer AEDs, TGB and ZNS had the next
highest rate of CSEs (15.4% and 8.6%, respectively).
As seen in Table 3, no ICSEs were reported with VGB, although
only 38 patients took VGB (in polytherapy). With the exception of
VGB, LTG was associated with the lowest ICSEs (2.5%) when LTG
was newly started as part of polytherapy. When LTG was compared
against other AEDs in head-to-head comparison, the rate of ICSEsUnivariate
95% CI
Multivariate
odds ratio
Multivariate
p-value
Multivariate
95% CI
1.09–1.65 1.35 0.006 1.09–1.68
0.40–0.98 0.42 0.001 0.25–0.70
0.95–2.00 1.05 0.81 0.71–1.57
1.09–2.03 1.24 0.197 0.89–1.73
0.98–2.65 1.57 0.088 0.94–2.63
1.04–1.89 1.33 0.074 0.97–1.82
1.07–2.50 1.38 0.158 0.88–2.17
1.03–4.18 2.02 0.056 0.98–4.19
0.05–.89 0.26 0.063 0.06–1.07
1.14–2.36 1.41 0.081 0.96–2.07
1.17–1.76 1.40 0.005 1.11–1.77
0.98–1.82 1.70 0.004 1.18–2.44
1.38–6.47 3.50 0.005 1.45–8.46
0.98–1.85 1.31 0.118 0.93–1.83
0.95–2.67 1.72 0.051 1.00–2.96
1.32–1.66 3.41 <0.001 2.44–4.78
rome, epilepsy risk factors, medical history, and psychiatric history. Only variables
ultivariate analysis have p-values bolded. p-values shown in red indicate a trend
Table 3
Comparison of incidence rates of ICSEs between total sample on AEDs newly started, sample on AEDs newly started as part of polytherapy and sample on AEDs newly started
and in monotherapy.
AED N of total sample % ICSE in
total sample
N in polytherapy % ICSE in
polytherapy
N in monotherapy % ICSE in
monotherapy
VGB 39 0.0 38 0.0 – –
LTG 1150 4.5 993 2.5 640 4.7
FBM 61 3.3 60 3.3 – –
OXC 259 6.2 217 3.2 111 9.1
CLB 204 3.4 203 3.4 – –
CBZ 258 5.0 216 4.2 139 3.6
LEV 908 5.2 832 6.4 269 5.5
PGB 295 4.5 286 4.2 31 3.2
LCM 137 5.1 135 4.4 – –
RFM 90 5.6 90 5.6 – –
GBP 306 5.2 277 5.1 79 2.5
PHT 180 9.4 136 5.9 100 11.0
VPA 237 7.2 205 6.3 96 6.3
ZNS 427 9.8 407 8.6 120 12.5
PB 46 10.9 44 9.1 – –
PRM 20 15.0 20 15.0 – –
TGB 27 14.8 26 15.4 – –
TPM 299 24.1 281 22.8 54 18.5
Cohort 2192 – 1871 – 1243 –
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; CLB: clobazam; FBM: felbamate; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine;
OXC: oxcarbazepine; PB: phenobarbital; PGB: pregabalin; PHT: phenytoin; PRM: primidone; RFM: ruﬁnamide; TGB: tiagabine; TPM: topiramate; VPA: valproate; ZNS:
zonisamide; Avg: average.
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p = 0.001), TGB (15.4%, p = 0.005), VPA (6.3%, p = 0.004), ZNS (8.6%,
p < 0.001) and TPM (22.8%, p < 0.001). Between ZNS and LEV, two
commonly prescribed newer AEDs, ZNS (8.6%) had a signiﬁcantly
higher rate of ICSEs when compared with LEV (4.2%, p = 0.002).
As seen in Table 4, when TPM was newly started as part of
polytherapy, it was 6.2 times more likely to be associated with
ICSEs than all other polytherapy regimens combined (p < 0.0001).Table 4
Comparison of ICSEs of AEDa to all other drug trials in patients newly started on
polytherapy (n = 1871).
AED Cases % ICSEs Odds
ratio
p-valuey 95% CI for OR
VGB 38 0.0 0 NS –
LTG 993 2.5 0.37 <0.0001 0.24–0.56
OXC 217 3.2 0.54 NS 0.25–1.16
FBM 60 3.3 0.57 NS 0.14–2.34
CLB 203 3.4 0.58 NS 0.27–1.25
CBZ 216 4.2 0.71 NS 0.36–1.40
LEV 832 4.2 0.68 0.04 0.48–0.99
PGB 286 4.2 0.71 NS 0.39–1.29
LCM 135 4.4 0.77 NS 0.33–1.75
GBP 277 5.1 0.88 NS 0.50–1.52
RFM 90 5.6 0.97 NS 0.39–2.42
PHT 136 5.9 1.04 NS 0.50–2.14
VPA 205 6.3 1.13 NS 0.63–2.01
ZNS 407 8.6 1.65 0.008 1.14–2.39
PB 44 9.1 1.67 NS 0.59–4.70
PRM 20 15.0 2.95 NS 0.86–10.13
TGB 26 15.4 3.05 NS 1.04–8.91
TPM 281 22.8 6.19 <0.0001 4.52–8.48
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; CLB: clobazam; FBM:
felbamate; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: lamo-
trigine; OXC: oxcarbazepine; PB: phenobarbital; PGB: pregabalin; PHT: phenytoin;
PRM: primidone; RFM: ruﬁnamide; TGB: tiagabine; TPM: topiramate; VPA:
valproate; ZNS: zonisamide; Avg: average.
Results are shown for AEDs newly started in 10 or more patients.
Signiﬁcant p-values (0.05) are in bold.
a Only AEDs taken in at least 20 or more patients are shown.
y Fisher exact test performed when expected value <5. Only values of p < 0.05 are
shown.ZNS was 1.65 times more likely to be associated with ICSEs
compared to other polytherapy regimens combined (p = 0.008). In
contrast, LEV and LTG were less likely to be associated with ICSEs
when compared to other polytherapy that did not include either
LEV (OR = 0.68, p = 0.04) or LTG (OR = 0.37, p < 0.0001).
3.2.2. Relative rates of ICSEs from AEDs newly started and in
monotherapy
The rates for ICSEs associated with AEDs newly started and in
monotherapy are shown (Table 3). TPM had the highest rate of
ICSEs (18.5%), followed by PHT (11%). When compared against
other AEDs in head-to-head comparison (Supplementary Table
3), the rate of CSE intolerability from TPM (18.5%) was higher
than that associated with CBZ (3.6%, p = 0.001), GBP (2.5%,
p = 0.003), LEV (5.5%, p = 0.003) and LTG (4.7%, p < 0.001). The
rate of ICSEs with PHT was signiﬁcantly higher than with GBP,
CBZ, and LTG. As in Table 5, patients on TPM monotherapy were
3.7 times more likely to experience ICSEs compared to all other
monotherapy regimens combined (p = 0.001). Patients on LTG
monotherapy were 37% less likely to report ICSEs (OR = 0.63,
p = 0.04), when compared to all other monotherapy trials
combined; rates were also low (but not signiﬁcant) with GBP,
PGB, CBZ AND LEV.
3.2.3. Relative rates of ICSEs from AEDs newly started and in
monotherapy, stratiﬁed by intellectual disability
When limiting the analysis to patients without intellectual
disability who had newly started AED as monotherapy (n = 1202 in
Supplementary Table 4), TPM again had the highest rate of ICSEs,
followed by PHT; GBP, PGB, and CBZ had the lowest rates of ICSEs.
Because only 41 patients with intellectual disability had newly
started an AED as monotherapy (with only 1 patient having ICSE),
we did not perform head to head comparison between AEDs.
3.2.4. Types of ICSEs
The frequencies of speciﬁc types of ICSEs associated with each
AED are shown in Table 6. Similar to what we found in our previous
investigation, the most frequent speciﬁc ICSE associated with TPM
was psychomotor/cognitive slowing (13.7%).
Table 5
Comparison of ICSEs of AEDa to all other drug trials in adult patients with epilepsy
newly started and in MonoTx (n = 1243).
AED Cases % ICSEs Odds ratio p-value* 95% CI for OR
GBP 79 2.5 0.38 NS 0.09–1.56
PGB 31 3.2 0.49 NS 0.07–3.66
CBZ 139 3.6 0.54 NS 0.21–1.34
LTG 640 4.7 0.63 0.04 0.41–0.97
LEV 269 5.5 0.86 NS 0.49–1.52
VPA 96 6.3 1.00 NS 0.43–2.34
ZNS 120 8.3 1.40 NS 0.71–2.76
OXC 111 9.1 1.53 NS 0.78–3.32
PHT 100 11.0 1.95 0.04 1.08–3.77
TPM 54 18.5 3.66 0.001 1.78–7.49
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; GBP: gabapentin; LEV:
levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; PHT: phenytoin; PGB:
pregabalin; TPM: topiramate; VPA: valproate; ZNS: zonisamide; Avg: average.
Results are shown for AEDs newly started in 10 or more patients.
Signiﬁcant p-values (0.05) are in bold.
a Only AEDs taken in at least 20 or more patients are shown.
* Fisher Exact Test performed when expected value <5. Only values of p < 0.05
are shown.
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Supplementary Tables 5 and 6 list the frequency of ICSEs that
occurred during the AED titration period, which we deﬁned as the
ﬁrst 8 weeks after initiation of an AED. Supplementary Tables 5 and
6 show data on percent of patients who had CSE attributed to AED,
percent of patients who had intolerable CSE, percent of patients
who had intolerable CSE during titration period (ﬁrst 8 weeks of
starting an AED), as well as those who discontinued versus those
who reduced AED dose but continued. The last group who
continued AED after reducing the dosage presumably had
sufﬁcient amelioration of cognitive condition and worthwhile
improvement in seizure control. For example, of 79 patients who
newly started GBP as monotherapy, 2.5% had intolerable CSE. Only
1.3% discontinued GBP, while 1.2% reduced GBP dose and
continued it. On the other hand, of 54 patients who newly started
TPM as monotherapy, 18.5% had ICSE. Most of those patients
discontinued (14.8%) TPM, while 3.7% chose to continue TPM.
Of those with ICSE, relatively small number of them reduced the
AED dose. For example, 22.8% of 281 patients on TPM as part ofTable 6
% of speciﬁc ICSEs by newly started AED in adults (n = 2192).
Side effect Aphasia/anomia/
word-ﬁnding
difﬁculty
Decreased
concentration
AED n
VGB 39 0 0 
LTG 1150 0.5 1.1 
FBM 61 0 0 
OXC 259 0.8 3.1 
CLB 204 0.5 1.0 
CBZ 258 1.6 1.6 
LEV 908 0.3 1.9 
PGB 295 1.0 0.7 
LCM 137 0 0.7 
RFM 90 0 1.1 
GBP 306 0 2.3 
PHT 180 1.7 5.6 
VPA 237 1.7 2.1 
ZNS 427 1.2 3.0 
PB 46 2.2 2.2 
PRM 20 0 0 
TGB 27 0 7.4 
TPM 299 3.3 4.7 
Abbreviations: AED: antiepileptic drug; CBZ: carbamazepine; CLB: clobazam; FBM: felb
OXC: oxcarbazepine; PB: phenobarbital; PGB: pregabalin; PHT: phenytoin; PRM: prim
valproate; ZNS: zonisamide.polytherapy had ICSEs, with 22.1% discontinuing TPM while 0.7%
reduced their TPM dose.
3.2.6. Effect of dose on ICSE
As seen in Supplementary Table 7, AED load did not differ
signiﬁcantly between patients with ICSE and patients without ICSE
for most AEDs. For VPA and ZNS, AED load was signiﬁcantly lower
in patients with ICSE than patients without intolerable CSE.
4. Discussion
In the present study we identiﬁed two predictors of intolerable
CSEs (ICSEs): lack of intellectual disability and use of AEDs in
polytherapy. Patients with intellectual disability, as assessed by
the treating epilepsy attendings, were less likely to report CSEs
than patients without intellectual disability, controlling for other
potential predictors in the model. This may be reﬂective of
difﬁculty detecting additional cognitive impairment in cognitively
disabled patients, likely related to underreporting by patients.
The rates of CSE proﬁles differed between AEDs. The highest
rate of ICSEs occurred with TPM, whether TPM was newly started
as part of a polytherapy or in monotherapy. When polytherapy
contained TPM as a newly started AED, it was six times more likely
to be associated with CSEs compared to polytherapy regimens that
did not include TPM. Monotherapy with TPM as a newly started
AED was 3.7 times more likely to be associated with CSEs than all
other newly started AEDs in monotherapy. Treatment-emergent
cognitive effects of TPM have been shown in a number of double-
blind placebo controlled trials, retrospective studies, meta-
analyses and post-marketing reports [2,9–24]. Investigations
directly comparing TPM to other AEDs performed in both epilepsy
and healthy subjects support our ﬁndings, showing TPM results in
signiﬁcantly more CSEs than GBP, LEV, LTG or VPA [25–31]. To our
knowledge, no other study has shown direct comparison of TPM to
most of the newly approved AEDs. Next, PHT had the second
highest rate of CSEs in monotherapy (11% of 100 patients).
Additionally, compared to other newer AEDs such as LEV and LTG,
ZNS was signiﬁcantly more likely to be associated with CSEs when
newly started in polytherapy. In the literature, language im-
pairment was present in two pilot studies while a single long-termDecreased
memory
Psychomotor/
cognitive
slowing
Confusion/
disorientation
0 0 0
2.5 1.2 0.3
1.6 0 1.6
2.7 0.4 1.2
1.0 1.0 1.0
2.3 1.2 0.4
2.3 1.6 0.8
1.0 1.7 0.3
2.9 2.2 1.5
0 2.2 2.2
2.3 0.7 1.0
5.6 1.1 0.6
3.4 2.9 0.5
2.8 4.9 0.7
6.5 2.2 0
5.0 5.0 5.0
3.7 3.7 7.4
5.4 13.7 2.0
amate; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine;
idone; RFM: ruﬁnamide; TGB: tiagabine; TPM: topiramate; VGB: vigabatrin; VPA:
A. Javed et al. / Seizure 29 (2015) 34–40 39prospective study showed 47% experienced delayed word recall on
ZNS after one year on monotherapy [32–34].
LTG, when used in polytherapy, was less likely to be associated
with CSEs compared to all other polytherapy regimens combined.
Monotherapy of LTG was about a third less likely to be associated
with CSEs compared to all other monotherapy combined. In two
prospective clinical trials, no CSEs were observed with LTG therapy
[35,36]. Notably, GBP, PGB, and CBZ had low or lower rates of CSE
than LTG, although not statistically signiﬁcant. One reason for the
lack of signiﬁcant association could be due to number of patients
taking these AEDs. Also note that the rate of CSEs associated with
OXC in monotherapy was higher than that for CBZ, approaching
signiﬁcance (p = 0.07) (Table 5).
Since our previous study, a number of new AEDs have been FDA
approved for seizure control. These include LCM, PGB, VGB, CLB,
and RFM. Cognitive impairment was infrequently reported when
LCM was used as part of polytherapy. In agreement with our
ﬁndings, randomized controlled trials did not show clear cognitive
impairment with LCM [37], while one retrospective study in
outpatients with epilepsy showed LCM’s CSE proﬁle to be
comparable to LTG [38]. None of 38 patients newly started on
VGB as part of polytherapy in our study had intolerable CSEs. In
prior studies in which VGB was compared to placebo, no signiﬁcant
difference in CSEs was found [39–41]. It is important to note that
the absence of CSE among 38 patients may have been confounded
by intellectual disability. Sixteen out of 38 patients on VGB had
intellectual disability, which may have made detection of CSE more
difﬁcult. Even if VGB has a low rate of CSE, the beneﬁt of VGB will
have to be weighed against the risk of irreversible visual ﬁeld
restrictions associated with VGB [42].
Studies examining tolerability of CLB have focused on pediatric
populations or adults with Lennox–Gastaut syndrome [4,43–46].
These studies suggest that little to no cognitive impairment is
associated with CLB. Since patients with intellectual disability are
less likely to report ICSEs, rate of ICSEs from CLB in other patient
population (i.e., those without intellectual disability) remains
unclear. In our study, ICSEs were relatively rare with CLB in
polytherapy. Similarly, much of the data on RFM is limited to
patients with Lennox–Gastaut syndrome.
Cognitive slowing was the most frequently cited type of ICSE for
TPM among our patients. Although marked cognitive slowing has
been associated with TPM [29], other studies have also reported a
reduction in verbal IQ, deterioration in verbal ﬂuency and
comprehension when assessed with neuropsychological testing
[24,47], which we did not test. We report the rates of CSE
attributed to an AED, the rates of ICSE, and the number of patients
with ICSE who discontinued the AED. While the majority of
patients experiencing ICSE chose to discontinue the AED, we
postulate that the patients with ICSE who reduced their dose
(instead of discontinuing the AED) felt that there was a worthwhile
improvement of seizure control to continue the AED.
There are some notable limitations in this study. First, this was a
retrospective study of adult outpatients. Thus, these results are not
neither generalizable to all epilepsy patients nor applicable to
children with epilepsy. To minimize the effect of recall bias, we
included only AEDs newly started at our center. Second, the
occurrence of CSEs and attribution to a newly started AED was
based on patient report and physician judgment. Among patients
with refractory epilepsy, ‘‘memory difﬁculties’’ are a common
complaint [48]. Therefore, it is difﬁcult to disentangle cognitive
side effect of a medication from cognitive dysfunction resulting from
refractory epilepsy among such patients. We relied on subjective
complaints of patients which were deemed by the treating physician
to be related to a newly started AED. As highlighted in a recent
publication by Witt and Helmstaedter [49], cognitive monitoring
with objective and validated neuropsychological measures may befeasible and will likely improve care of patients. However, a
systematic approach of assessing cognitive function before and after
the introduction of an AED with validated instrument has not been
incorporated in clinical practice. Third, CSE reporting might have
differed depending on patient expectations or physician bias. For
example, patients who were provided with the expectation of possible
CSEs may have been more likely to report CSEs after initiating an AED
than patients who were reassured about the small likelihood of
possible CSEs. In addition, it is very difﬁcult if not impossible to account
for physician bias when blaming a given AED in patients on
polytherapy. However, the monotherapy results were very similar
to the polytherapy results, and the large number of physicians involved
should reduce this bias. Fourth, some AEDs were infrequently used
(e.g., TGB, VGB, RFM, and PRM), so the sample size of patients varied
across different drugs (Table 1), making it difﬁcult to detect CSEs in
infrequently used AEDs. Lastly, possibility existed that patients with
ICSE could have been on higher doses of AED than patients without
ICSE. One way to address this issue was by comparing the AED load,
calculated as AED dose at time of side effect divided by WHO deﬁned
daily dose of that medication, between patients with and without
ICSE. No signiﬁcant differences in AED load was found between
patients with and without ICSE. We also provided the average
maximum dose used for each AED, reﬂecting a local practice pattern
among the treating physicians at our study site (Table 1).
Despite these limitations, the method of ascertainment of CSEs in
the current study is similar to the manner in which CSEs are
determined in routine daily care of patients with epilepsy; any CSEs
bothersome enough for the patient to report to their physician were
in fact documented and thus reported in this study. Thus, the results
should be directly applicable to clinical practice.
The strength of this study is that we were able to examine the
occurrence of CSEs for almost all FDA-approved AEDs and compare
the relative rates among them in a large cohort of outpatients with
epilepsy. Although a randomized, double-blinded trial comparing
all the AEDs with standard dosing would be ideal to determine the
difference in CSEs, such a study would be prohibitively large and
expensive.
5. Conclusion
Our results suggest that TPM was most likely to be associated
with intolerable CSEs when used in poly- or monotherapy. Not
surprisingly, use of AED in polytherapy was a signiﬁcant predictor
of intolerable CSEs. Patients with intellectual disability were less
likely to report CSEs. Additionally, ICSEs tended to occur outside
the window of AED titration period and did not necessarily occur as
a result of patients taking a higher dose of AED.
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